文献速递胸部肿瘤

Rezivertinib(BPI-7711)治疗EGFR T790M突变晚期非小细胞肺癌的安全性、疗效与药代动力学:1期剂量递增与剂量扩展研究

Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.
PubMed 文献 · J Thorac Oncol · 2022-02-15

本研究为在中国20个中心开展的1期剂量递增与扩展研究,评估Rezivertinib(BPI-7711)在EGFR T790M突变晚期非小细胞肺癌患者中的安全性、疗效与药代动力学。172例患者接受每日一次口服30-300mg,未出现剂量限制性毒性,盲态独立中心评估的客观缓解率为59.3%,中位无进展生存期为9.7个月,安全性总体可控。

要点

  • 剂量递增阶段19例、扩展阶段153例,共172例EGFR T790M突变晚期非小细胞肺癌患者。
  • 未发生剂量限制性毒性;治疗相关不良事件发生率82.0%,≥3级占17.4%。
  • 盲态独立中心评估客观缓解率59.3%(102/172),中位无进展生存期9.7个月。

核心结论

  • Rezivertinib在EGFR T790M突变晚期非小细胞肺癌患者中显示出有前景的疗效和可控的安全性,需进一步研究。

研究设计与样本

  • 1期剂量递增与剂量扩展研究(NCT03386955),在中国20个中心开展。
  • 剂量递增阶段19例采用标准3+3设计原则,剂量扩展阶段153例,共172例患者。
  • 患者接受六种口服剂量水平(30mg、60mg、120mg、180mg、240mg、300mg)每日一次给药,直至疾病进展、不可耐受毒性或患者退出。
  • 主要终点:剂量递增阶段的安全性,以及总研究人群经盲态独立中心评估的客观缓解率。
  • 入组时间为2017年9月11日至2019年8月23日,数据截止日期为2020年6月15日。

主要发现

  • 剂量递增阶段未发生剂量限制性毒性。
  • 治疗相关不良事件发生率为82.0%(141/172),≥3级占17.4%(30/172)。
  • 最常见的≥3级治疗相关不良事件为中性粒细胞计数降低(2.9%)、白细胞减少(2.9%)和肺炎(2.9%)。
  • 盲态独立中心评估的总体客观缓解率为59.3%(102/172,95%CI:51.6-66.7)。
  • 中位无进展生存期为9.7个月(95%CI:8.3-11.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M mutations. This study was designed to evaluate the safety, efficacy, and pharmacokinetics of rezivertinib for patients having advanced NSCLC with EGFR T790M mutation. METHODS: This phase 1 study (NCT03386955) was conducted across 20 sites in the People's Republic of China. Patients received rezivertinib at six oral dose levels (30 mg, 60 mg, 120 mg, 180 mg, 240 mg, 300 mg) once daily until disease progression, unacceptable toxicity, or patient withdrawal. The primary end points were safety for the dose-escalation phase and objective response rate by the blinded independent central review for the total study population. RESULTS: A total of 19 patients in dose-escalation phase using the standard 3 + 3 design principle and 153 patients in dose-expansion phase were enrolled from September 11, 2017, to August 23, 2019. The data cutoff date was on June 15, 2020. No dose-limiting toxicity occurred in the dose-escalation phase. The treatment-related adverse events were observed in 82.0% (141 of 172) of patients, and 17.4% (30 of 172) had grade greater than or equal to 3, among which decreased neutrophil count (2.9%), leukopenia (2.9%), and pneumonia (2.9%) were the most common. The overall blinded independent central review-evaluated objective response rate was 59.3% (102 of 172, 95% confidence interval: 51.6-66.7), and the median progression-free survival was 9.7 (95% confidence interval: 8.3-11.1) months. CONCLUSIONS: Rezivertinib was found to have promising efficacy with a manageable safety profile in patients with EGFR T790M-mutated advanced NSCLC. Further study is warranted.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Shi Y, Zhao Y, Yang S, et al. Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. J Thorac Oncol. 2022. PMID: 35181498. doi:10.1016/j.jtho.2022.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。